Next-generation sequencing to assess HIV tropism

Current Opinion in HIV and AIDS

Volumn 7, Issue 5, 2012, Pages 478-485

  Swenson, Luke C ^a   Däumer, Martin ^b   Paredes, Roger ^c  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^b Rheinland Pfälzische Technische Universität Kaiserslautern Landau   (Germany)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

CCR5; CXCR4; deep sequencing; genotype; maraviroc; tropism; V3

Indexed keywords

CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; EFAVIRENZ; MARAVIROC; VIRUS DNA;

CLINICAL PRACTICE; DIAGNOSTIC VALUE; DNA SEQUENCE; ENVELOPE GENE; GENE SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INTRACELLULAR SPACE; MICELLE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PLASMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; VIRAL TROPISM;

ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENOTYPE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV; HIV INFECTIONS; HUMANS; VIRAL TROPISM; VIROLOGY;

EID: 84865617205     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328356e9da     Document Type: Review

References (55)

1. The Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: A collaborative analysis of 14 cohort studies. Lancet 2008; 372:293- 299.
2. Hogg R, Samji H, Cescon A, et al. Temporal changes in life expectancy of HIV individuals: North America. In: 19th Conference on Retroviruses and Opportunistic Infections. CROI; 2012; Abstract 137.
3. Schuitemaker H, van 't Wout AB, Lusso P. Clinical significance of HIV-1 coreceptor usage. J Transl Med 2011; 9 (Suppl. 1): S5.
4. Saag M, Goodrich J, Fá tkenheuer G, et al. A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV- 1. J Infect Dis 2009; 199:1638-1647.
5. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359:1429-1441.
6. Fátkenheuer G, Nelson M, Lazzarin A, et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008; 359:1442- 1455.
7. Cooper D, Heera J, Goodrich J, et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviralnaive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 2010; 201: 803-813.
8. Swenson LC, Mo T, Dong WWY, et al. Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: A reanalysis of the MERIT trial of maraviroc. Clin Infect Dis 2011; 53:732-742
9. .Swenson LC, Mo T, Dong WWY, et al. Deep sequencing to infer HIV-1 coreceptor usage: Application to three clinical trials of maraviroc in treatmentexperienced patients. J Infect Dis 2011; 203:237-245
10. Heera J, Harrigan P, LewisM, et al. Predicting maraviroc responses according to number or percentage of X4-using virus among treatment-experienced patients. In: 19th Conference on Retroviruses and Opportunistic Infections. 2011; Abstract P 593.
11. McGovern RA, Thielen A, Mo T, et al. Population-based V3 genotypic tropism assay: A retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. AIDS 2010; 24:2517-2525.
12. McGovern RA, Dong W, Mo T, et al. Optimization of clinically relevant cutpoints for the determination of HIV co-receptor usage to predict maraviroc responses in treatment experienced (TE) patients using population V3 genotyping. In: European AIDS Clinical Society. 2009; Poster PE3.4/8.
13. Palmer S, Kearney M, Maldarelli F, et al. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol 2005; 43:406-413.
14. Tsibris AMN, Korber B, Arnaout R, et al. Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS One 2009; 4:e5683.
15. Rozera G, Abbate I, Bruselles A, et al. Massively parallel pyrosequencing highlights minority variants in the HIV-1 env quasispecies deriving from lymphomonocyte sub-populations. Retrovirology 2009; 6:15.
16. Vandenbroucke I, Van Marck H, Mostmans W, et al. HIV-1 V3 envelope deep sequencing for clinical plasma specimens failing in phenotypic tropism assays. AIDS Res Ther 2010; 7:4.
17. Dáumer M, Kaiser R, Klein R, et al. Genotypic tropism testing by massively parallel sequencing: qualitative and quantitative analysis. BMC Med Inform Decis Mak 2011; 11:30
18. Margulies M, Egholm M, Altman WE, et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature 2005; 437:376-380.
19. Glenn TC. Field guide to next-generation DNA sequencers. Mol Ecol Resour 2011; 11:759-769
20. Vandenbroucke I, Van Marck H, Verhasselt P, et al. Minor variant detection in amplicons using 454 massive parallel pyrosequencing: experiences and considerations for successful applications. Biotechniques 2011; 51:167- 177.
21. Zhong X, Lewis M, Dong W, et al. The influence of PCR amplification variation on the ability of population-based PCR to detect non-R5 HIV. In: 8th European HIV Drug Resistance Workshop; 2010.
22. Swenson LC, Moores A, Low AJ, et al. Improved detection of CXCR4- using HIV by V3 genotyping: Application of population-based and 'deep' sequencing to plasma RNA and proviral DNA. J Acquir Immune Defic Syndr 2010; 54:506-510.
23. Jabara CB, Jones CD, Roach J, et al. Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID. Proc Natl Acad Sci USA 2011; 108:20166-20171.
24. Thielen A, Lengauer T. Geno2pheno[454]: A Web server for the prediction of HIV-1 coreceptor usage from next-generation sequencing data. Intervirology 2012; 55:113-117.
25. Lengauer T, Sander O, Sierra S, et al. Bioinformatics prediction of HIV coreceptor usage. Nat Biotechnol 2007; 25:1407-1410.
26. Henn MR, Boutwell CL, Charlebois P, et al. Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. PLoS Pathog 2012; 8:e1002529.
27. Zagordi O, Klein R, Dáumer M, Beerenwinkel N. Error correction of nextgeneration sequencing data and reliable estimation of HIV quasispecies. Nucleic Acids Res 2010; 38:7400-7409. doi: 10.1093/nar/gkq655.
28. Delobel P, Saliou A, Nicot F, et al. Minor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failure. PLoS One 2011; 6:e21655.
29. Shendure J, Ji H. Next-generation DNA sequencing. Nat Biotechnol 2008; 26:1135-1145.
30. Zhou X, Ren L, Li Y, et al. The next-generation sequencing technology: A technology review and future perspective. Sci China C Life Sci 2010; 53:44-57.
31. Fedurco M, Romieu A, Williams S, et al. BTA, a novel reagent for DNA attachment on glass and efficient generation of solid-phase amplified DNA colonies. Nucleic Acids Res 2006; 34:e22.
32. Dressman D, Yan H, Traverso G, et al. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci USA 2003; 100:8817- 8822.
33. Peckham HE, Mclaughlin SF, Ni JN, et al. SOLiDTM sequencing and 2-base encoding [Internet]. SOLiDTM Sequencing Chemistry, Applied Biosystems [date unknown], [no volume]. Applied Biosystems. Specification sheet - 5500 series genetic analysis systems. 2011; ABI.
34. Pou C, Codon er FM, Thielen A, et al. High resolution tropism kinetics by quantitative deep sequencing in HIV-1-infected subjects initiating suppressive first-line antiretroviral therapy. In: 17th Conference on Retroviruses and Opportunistic Infections. 2010; Abstract 544.
35. Bunnik EM, Swenson LC, Edo-Matas D, et al. Detection of inferred CCR5- and CXCR4-using HIV-1 variants and evolutionary intermediates using ultradeep pyrosequencing. PLoS Pathog 2011; 7:e1002106.
36. Schapiro JM, Boucher CA, Kuritzkes DR, et al. Baseline CD4 T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients. Antivir Ther 2011; 16:395-404.
37. Verhofstede C, Brudney D, Reynaerts J, et al. Concordance between HIV-1 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA. HIV Med 2011; 12:544-552.
38. Toma J, Frantzell A, Hoh R, et al. Determining HIV-1 coreceptor tropism using PBMCproviral DNA derived from aviremic blood samples. In: 17th Conference on Retroviruses and Opportunistic Infections. CROI; 2010; Abstract 541.
39. Parisi SG, Andreoni C, Sarmati L, et al. HIV coreceptor tropism in paired plasma, peripheral blood mononuclear cell, and cerebrospinal fluid isolates from antiretroviral-naíve subjects. J Clin Microbiol 2011; 49:1441-1445.
40. Paar C, Geit M, Stekel H, Berg J. Genotypic prediction of human immunodeficiency virus type 1 tropism by use of plasma and peripheral blood mononuclear cells in the routine clinical laboratory. J Clin Microbiol 2011; 49:2697-2699.
41. Raymond S, Delobel P, Mavigner M, et al. CXCR4-using viruses in plasma and peripheral blood mononuclear cells during primary HIV-1 infection and impact on disease progression. AIDS (London, England) 2010; 24:2305-2312.
42. Swenson L, McGovern R, James I, et al. Genotypic analysis of cellular HIV V3 DNA to predict virologic response to maraviroc: performance of populationbased and 454 deep V3 sequencing. In: 18th Conference on Retroviruses and Opportunistic Infections. CROI; 2011; Abstract 668.
43. Vandekerckhove L, Verhofstede C, Demecheleer E, et al. Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment. J Antimicrob Chemother 2011; 66:265-272.
44. Abbate I, Rozera G, Tommasi C, et al. Analysis of co-receptor usage of circulating viral and proviral HIV genome quasispecies by ultra-deep pyrosequencing in patients who are candidates for CCR5 antagonist treatment. Clin Microbiol Infect 2011; 17:725-731.
45. Kirby Institute, ViiV Healthcare, Pfizer. Maraviroc Switch Collaborative Study (MARCH) [Internet]. ClinicalTrials.gov. 2012 [no volume].
46. Bellecave P, Paredes R, Soriano V, et al. Determination of HIV-1 tropism from proviral HIV-1 DNA in patients with suppressed plasma HIV-1 RNA and its impact on virologic responses to maraviroc. In: 19th Conference on Retroviruses and Opportunistic Infections. CROI. 2012; Abstract 716.
47. Saliou A, Delobel P, Dubois M, et al. Concordance between two phenotypic assays and ultradeep pyrosequencing for determining HIV-1 tropism. Antimicrob Agents Chemother 2011; 55:2831-2836.
48. Li JZ, Paredes R, Ribaudo HJ, et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: A systematic review and pooled analysis. JAMA 2011; 305:1327-1335
49. Westby M Lewis M Whitcomb J et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a Pretreatment CXCR4-using Virus Reservoir. J Virol 2006; 804909-4920.
50. Archer J, Rambaut A, Taillon BE, et al. The evolutionary analysis of emerging low frequency HIV-1 CXCR4 using variants through time - an ultra-deep approach. PLoS Comput Biol 2010; 6:e1001022.
51. Baatz F, Struck D, Lemaire M, Landtsheer SD. Rescue of HIV-1 long-time archived X4 strains to escape maraviroc. Antivir Res 2011; 92:488-492. doi: 10.1016/j.antiviral.2011.10.003.
52. Swenson LC, Brumme CJ, Woods CK, et al. Genotypic analysis of V3 in patients experiencing virologic failure on maraviroc-containing regimens and correlation with pretreatment deep sequencing results. In: International HIV & Hepatitis Virus Drug Resistance Workshop and Curative Strategies. 2010.
53. Wilkin TJ, Goetz MB, Leduc R, et al. Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity. Clin Infect Dis 2011; 52:925-928.
54. Whitcomb JM, Huang W, Fransen S, et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007; 51:566-575.
55. Gonzalez-Serna A, McGovern RA, Harrigan PR, et al. Correlation of the virological response to short-term maraviroc monotherapy with standard and deep sequencing-based genotypic tropism methods. Antimicrob Agents Chemother 2012; 56:1202-1207.